Mcl-1 and Bcl-xL coordinately regulate megakaryocyte survival

Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes

(2011) Z.-J. Liu et al.   BLOOD

BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation

(2011) M. Vogler et al.   BLOOD

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

(2011) S. M. Schoenwaelder et al.   BLOOD

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets

(2011) Emma C. Josefsson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

(2011) J. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR

(2010) Andrew M. Petros et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Platelet senescence is regulated by an internal timer, not damage inflicted by hits

(2010) M. R. Dowling et al.   BLOOD

Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling

(2010) C. C. Bertozzi et al.   BLOOD

Platelets Play an Essential Role in Separating the Blood and Lymphatic Vasculatures During Embryonic Angiogenesis

(2010) Laura Carramolino et al.   CIRCULATION RESEARCH

Drugs targeting Bcl-2 family members as an emerging strategy in cancer

(2010) Brian Leber et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

Platelet senescence and phosphatidylserine exposure

(2010) Swapan Kumar Dasgupta et al.   TRANSFUSION

Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function

(2009) S. M. Schoenwaelder et al.   BLOOD

Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage

(2009) E. A. Kruse et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

BCL-2 family antagonists for cancer therapy

(2008) Guillaume Lessene et al.   NATURE REVIEWS DRUG DISCOVERY

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY